Lite Strategy (LITS) Share-based Compensation (2010 - 2026)
Lite Strategy (LITS) posted Share-based Compensation of $270000.0 for Q1 2026, up 101.72% on a QoQ basis from -$15.7 million in Q4 2025, and down 85.41% year-over-year from $1.9 million in Q1 2025.
Analysis
Lite Strategy (LITS) Share-based Compensation (2010 - 2026) Analysis & Trends
Lite Strategy has reported Share-based Compensation for 17 years, with the latest figure at $270000.0 in Q1 2026.
- On a quarterly basis, Share-based Compensation fell 85.41% year-over-year to $270000.0 in Q1 2026; TTM through Mar 2026 was $866000.0, a 53.21% decrease from a year earlier, with the FY2025 full-year figure at $869148.0, down 61.85% from the prior year.
- Share-based Compensation was $270000.0 for Q1 2026 at Lite Strategy, up from -$15.7 million in the prior quarter.
- The five-year high for Share-based Compensation was $1.4 billion in Q4 2023, with the low at -$15.7 million in Q4 2025.
- Average Share-based Compensation over 5 years is $177.3 million, with a median of $1.4 million recorded in 2023.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 109520.32% in 2024, then tumbled 1744.14% in 2025.
- Over 5 years, Share-based Compensation stood at $25.4 million in 2022, then surged by 5401.89% to $1.4 billion in 2023, then plunged by 99.93% to $954723.0 in 2024, then sank by 1744.14% to -$15.7 million in 2025, then jumped by 101.72% to $270000.0 in 2026.
- The last three Share-based Compensation figures came in at $270000.0 (Q1 2026), -$15.7 million (Q4 2025), and $16.2 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | 270,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 270,000.00 |
| Dec 31, 2025 | -15.70 Mn |
| Sep 30, 2025 | 16.22 Mn |
| Jun 30, 2025 | 78,000.00 |
| Mar 31, 2025 | 1.85 Mn |
| Dec 31, 2024 | 954,723.00 |
| Sep 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 397,000.00 |
| Mar 31, 2024 | 1.37 Bn |
| Dec 31, 2023 | 1.40 Bn |
| Sep 30, 2023 | 1.45 Mn |
| Mar 31, 2023 | 1.25 Mn |
| Dec 31, 2022 | 25.40 Mn |
| Sep 30, 2022 | 11.83 Mn |
| Jun 30, 2022 | 650,000.00 |
| Mar 31, 2022 | 20.59 Mn |
| Dec 31, 2021 | 27.38 Mn |
| Sep 30, 2021 | 20.64 Mn |
| Jun 30, 2021 | 1.56 Mn |
| Mar 31, 2021 | 2.65 Mn |